Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with moderate to severe asthma

T. Pertseva, K. Gashynova, O. Gurzhiy, K. Kaiser (Dnipropetrovsk, Ukraine; Muttenz, Switzerland)

Source: Annual Congress 2009 - Towards improving asthma control
Session: Towards improving asthma control
Session type: E-Communication Session
Number: 279
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Pertseva, K. Gashynova, O. Gurzhiy, K. Kaiser (Dnipropetrovsk, Ukraine; Muttenz, Switzerland). Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with moderate to severe asthma. Eur Respir J 2009; 34: Suppl. 53, 279

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

RIDGE Helen - 13.09.2009 10:18
Question
I see this is a new fixed dose combination. Please could you advise whether it is currently licensed for use and in which countries it is available? Thank you
You must Login to comment this presentation.


Related content which might interest you:
Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with mild to moderate asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009

Once-daily, high-dose inhaled fluticasone propionate and salmeterol in patients having moderate asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 125s
Year: 2004

Efficacy and safety of ciclesonide compared with fluticasone propionate in patients with moderate to severe asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 206s
Year: 2006

Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 513s
Year: 2004

Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 292s
Year: 2005

Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010

Aerosolized fluticasone propionate therapy in acute moderate exacerbations of asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 45s
Year: 2002

Long-term treatment with fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy is well-tolerated and provides sustained effectiveness in paediatric patients with asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011


The salmeterol/fluticasone propionate combination 50/100 μg b.i.d is effective as initial maintenance therapy in mild and moderate asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001

Fluticasone propionate/formoterol fumarate combination therapy is more effective than fluticasone propionate alone in the treatment of asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Once daily ciclesonide delivered via pMDI is effective and safe for the treatment of mild-to-moderate persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 208s
Year: 2006

Budesonide and formoterol in a single inhaler controls exacerbations more effectively than a higher dose of inhaled corticosteroids alone, in mild-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 43s
Year: 2001

Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010


Efficacy of high-dose inhaled fluticasone propionate in Indian patients having moderate asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 305s
Year: 2002

Fluticasone furoate (FF), an inhaled corticosteroid (ICS), demonstrates efficacy in asthma patients symptomatic on moderate doses of ICS therapy
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010

Comparison of salmeterol/fluticasone propionate (sal/fp) combination versus monotherapy with fluticasone propionate (fp) in patients with mild to moderate asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009

Comparison of once-daily ciclesonide 160 μg versus twice-daily fluticasone propionate 88 μg in children with moderate to severe asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 711s
Year: 2006

Budesonide and formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroid in mild-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 159s
Year: 2001